Phathom Pharmaceuticals (PHAT) Receivables - Net (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has 4 years of Receivables - Net data on file, last reported at $80.7 million in Q1 2026.

• On a quarterly basis, Receivables - Net rose 121.99% year-over-year to $80.7 million in Q1 2026; TTM through Mar 2026 was $80.7 million, a 121.99% increase from a year earlier, with the FY2025 full-year figure at $78.1 million, up 101.38% from the prior year.
• Receivables - Net for Q1 2026 stood at $80.7 million, up from $78.1 million in the prior quarter.
• Over the last five years, Receivables - Net for PHAT reached as high as $80.7 million in Q1 2026 and fell as low as $1.6 million in Q4 2023.
• Historically, Receivables - Net has averaged $37.5 million across 4 years, with a median of $36.0 million in 2024.
• Across the five-year window, Receivables - Net soared 2077.52% in 2024 and jumped 119.18% in 2025, its largest moves.
• Year by year, Receivables - Net stood at $1.6 million in 2023, then surged by 2077.52% to $35.6 million in 2024, then jumped by 119.18% to $78.1 million in 2025, then gained by 3.32% to $80.7 million in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $80.7 million in Q1 2026, $78.1 million in Q4 2025, and $55.8 million in Q3 2025.